Business Context and Reporting Period
This Form 8-K Current Report for Sanara Medtech Inc. (SMTI) covers events occurring on September 10, 2024, with a report date of September 11, 2024. The filing details a strategic investment in a medical device company and a subsequent debt drawdown to fund the transaction.
Key Financial Metrics and Transactions
- Investment: Sanara CMP LLC (a wholly-owned subsidiary) purchased 100,674.72 common units in ChemoMouthpiece, LLC (CMp) for $5.0 million, representing approximately 6.64% of CMp's outstanding membership interest.
- Debt Financing: On September 4, 2024, the Company executed a "Second Borrowing" of $15.5 million under an existing Term Loan Agreement with CRG Servicing LLC.
- Loan Terms: The loan facility totals up to $55.0 million. Both the First Borrowing ($15.0 million) and Second Borrowing bear interest at 13.25% per annum with a maturity date of May 30, 2029.
- Future Capacity: Subject to conditions, the Company retains the right to draw a third borrowing of up to $24.5 million prior to June 30, 2025.
- Use of Proceeds: $5.0 million of the Second Borrowing funded the CMp investment; remaining proceeds are designated for permitted acquisitions and general working capital.
Material Changes and Strategic Agreements
Concurrent with the investment, the Company entered into an Exclusive Distribution Agreement appointing SI Healthcare Technologies, LLC (a 50/50 joint venture between Sanara and InfuSystem) as the sole U.S. distributor of CMp's Standard Chemo Regiment Kits for a five-year term. This agreement includes exclusive intellectual property rights for the resale and use of the Chemo Mouthpiece® oral cryotherapy device in the United States.
Outlook, Risks, and Management Commentary
The filing indicates management's intent to utilize remaining debt proceeds for "permitted acquisition opportunities," suggesting a continued strategy of growth through M&A. The filing does not provide specific revenue guidance or profit margins for the current period, as it is a current report focused on specific corporate events rather than periodic financial results. The high interest rate (13.25%) on the term loan represents a significant cost of capital that will impact future liquidity and profitability.
Investor Verification Checklist
- Verify the exact terms and conditions required to access the remaining $24.5 million borrowing capacity under the Loan Agreement.
- Review the full text of the Unit Purchase Agreement and Exclusive Distribution Agreement (Exhibit 10.1 referenced in prior filings) to understand covenants and exit strategies.
- Assess the impact of the 13.25% interest expense on the Company's future cash flow and EBITDA.
- Confirm the commercialization timeline and regulatory status of the Chemo Mouthpiece® device in the U.S. market.
- Monitor the Company's cash burn rate relative to the new debt obligations and the timeline for the next potential borrowing.